HLVX Stock Summary and Trading Ideas (Hillevax | NASDAQ:HLVX)

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Hillevax trades on the NASDAQ stock market under the symbol HLVX.

As of February 7, 2025, HLVX stock price declined to $1.87 with 116,205 million shares trading.

HLVX has a beta of 1.05, meaning it tends to be more sensitive to market movements. HLVX has a correlation of 0.00 to the broad based SPY ETF.

HLVX has a market cap of $93.10 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that HLVX belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.

HLVX has underperformed the market in the last year with a price return of -87.6% while the SPY ETF gained +23.1%. HLVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.6% and -4.1%, respectively, while the SPY returned +2.0% and -1.5%, respectively.

HLVX support price is $1.87 and resistance is $1.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HLVX shares will trade within this expected range on the day.